Back to Newsroom

Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Resunab™ will be tested for efficacy and safety in a Phase 2 clinical study in systemic lupus erythematosus (SLE). SLE is a prototypic autoimmune disease that can manifest with wide-ranging symptoms involving multiple organ systems.


Read more here.